

Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity & Clinical Trials Insight 2026

<https://marketpublishers.com/r/G8F829EECFDDEN.html>

Date: August 2021

Pages: 195

Price: US\$ 2,400.00 (Single User License)

ID: G8F829EECFDDEN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

“Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity & Clinical Trials Insight 2026” Report Highlights:

Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026

Role of FGFR Inhibitors in Cancer Therapy

Global FGFR Market Assessment (US\$) by Region & Cancer Type

Clinical & Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre & Truseltiq)

Dosage & Drug Price Insight on Approved FGFR Inhibitors

Comprehensive Clinical Trials Insight by Company, Country, Phase & Patient Segment: 53 Drugs in Trials

Recent breakthrough with respect to small molecule based therapy in the oncology segment has set up remarkable achievements in terms of improving the cancer survival rate. The FGFR inhibitors are considered as one of advanced anticancer therapy, which belongs to the class of receptor kinase inhibiting small molecules and now widely accepted for the treatment of various cancer types including bladder cancer, breast cancer, lung cancer gastric cancer, lymphoma, myeloma etc. In a short period of time,

FGFR inhibitors has made its way through all the challenges and led to a stage where the availability of the therapy is highly appreciated and praised.

The mutation or over expression of FGFR makes them ideal target for management of cancer and most of the researchers exploring the therapeutic potential of this class concluded the beneficial effects of this approach. Further, the FGFR alterations are also observed in rare cancers and hence this approach has potential to play a crucial role in the management of untreatable rare types of cancers. Currently, the market of FGFR inhibitors is at nascent stage, which is driven by the sales of 3 approved products of this class i.e. Balversa, Pemazyre and Truseltiq. Balversa is recommended for management of bladder cancer while Pemazyre and Truseltiq are recommended for the management of rare cancer termed as Cholangiocarcinoma. Many new drugs of this class are also believed to get orphan designation in upcoming years, which further boost the market size of this segment.

Balversa is expected to lead the market segment as its sales value is believed to increase exponentially after its approval in the leading regions including Europe and Japan. The estimated market size of FGFR inhibitor is about US\$ 100 Million in year 2020 and it is believed to grow with CAGR of more than 80% during the next 6 years as most of the market related factors are indicating towards the increasing acceptance of this segment in near future. Further, US will lead FGFR market due to availability of huge cancer burden and leading pharmaceutical companies. The drug approval process is now simplified in US due to availability of all the three drugs of this class and hence most of the new FGFR inhibitors will first get approval in this region.

With an aim of improving the market penetrability and commercialization of FGFR inhibitors, the leading pharmaceutical companies are expected to collaborate with CROs and regional pharmaceutical companies of developing countries, which will increase the market size of this novel segment in regions such as Asia-Pacific, Middle-East and Latin America. The leading pharmaceutical companies working in this sector are Amgen, Astem pharma, AstraZenca, Bayer, BMS, Incyte, Roche, Taiho, Janssen pharmaceuticals, Novartis etc. while many other companies are working on FGFR inhibitors in preclinical studies.

“Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity & Clinical Trials Insight 2026” report involves in depth analysis of the various parameters related to this segment along with the analysis of current as well as future market opportunity. The report also analyzes the wide range of applications of this class in cancer management along with the clinical trends, market drivers, and possible challenges

related to FGFR inhibitors market. Further, multiple parameters are considered to forecast and analyze the global, regional and indication based market size for FGR inhibitors drugs.

Contents

1. INTRODUCTION TO FGFR INHIBITORS

- 1.1 Overview
- 1.2 Evolution of FGFR Inhibitors

2. FGFR INHIBITORS - MECHANISM OF ACTION

3. ROLE OF FGFR INHIBITORS IN CANCER THERAPY

- 3.1 AZD4547
- 3.2 E7090
- 3.3 Debio 1347
- 3.4 Futibatinib
- 3.5 Rogaratinib
- 3.6 Derazantinib
- 3.7 RLY-4008
- 3.8 CPL304110

4. GLOBAL FGFR INHIBITOR MARKET ANALYSIS

- 4.1 Current Market Scenario
- 4.2 Future Market Opportunity

5. GLOBAL FGFR INHIBITORS MARKET OPPORTUNITY BY REGION

- 5.1 US
- 5.2 Europe
- 5.3 Japan
- 5.4 Rest of World

6. GLOBAL FGFR INHIBITORS MARKET OPPORTUNITY BY CANCER

- 6.1 Cholangiocarcinoma
- 6.2 Urothelial Carcinoma
- 6.3 Lymphoma
- 6.4 Lung Cancer

7. BALVERSA - FIRST APPROVED FGFR INHIBITOR 2019

- 7.1 Overview
- 7.2 Patent Insight

8. BALVERSA - COMERCIAL AVAILABILITY, DOSAGE & PRICE ANALYSIS

9. PEMAZYRE - SECOND APPROVED FGFR INHIBITOR 2020

- 9.1 Overview
- 9.2 Patent Insight

10. PEMAZYRE - COMMERCIAL INFORMATION

- 10.1 Dosage & Price Analysis
- 10.2 Sales Analysis

11. TRUSELTIQ - THIRD APPROVED FGFR INHIBITOR DRUG 2021

- 11.1 Overview
- 11.2 Patent Insight

12. TRUSELTIQ - COMMERCIAL AVAILABILITY, DOSAGE & PRICE ANALYSIS

13. GLOBAL SALES FORECAST - 2021 TILL 2026

- 13.1 Belvesra
- 13.2 Pemazyre
- 13.3 Truseltiq

14. FGFR INHIBITORS – ONGOING CLINICAL TRIALS

- 14.1 By Phase
- 14.2 By Development Status
- 14.3 By Region

15. GLOBAL - FGFR INHIBITORS IN CLINICAL TRIALS

- 15.1 Research

- 15.2 Preclinical
- 15.3 Phase-I
- 15.4 Phase-I/II
- 15.5 Phase-II
- 15.6 Phase-II/III
- 15.7 Phase-III
- 15.8 Preregistration

16. MARKETED FGFR INHIBITORS DRUGS CLINICAL INSIGHT

17. GLOBAL FGFR INHIBITORS MARKET DYNAMICS

- 17.1 Drivers for Global FGFR Inhibitors Market
- 17.2 Global FGFR Inhibitors Market Challenges

18. GLOBAL FGFR INHIBITORS MARKET FUTURE OUTLOOK

19. COMPETITIVE LANDSCAPE

- 19.1 Amgen
- 19.2 Astex Pharmaceuticals
- 19.3 AstraZeneca
- 19.4 Bayer
- 19.5 Blueprint Medicine
- 19.6 Boehringer Ingelheim International
- 19.7 Bristol Mayer Squibb
- 19.8 Incyte Corporation
- 19.9 Janssen Pharmaceuticals
- 19.10 Novartis International
- 19.11 Pfizer Inc
- 19.12 Roche
- 19.13 Taiho
- 19.14 TransThera Biosciences

List Of Figures

LIST OF FIGURES

Figure 1-1: History of FGFR Inhibitors

Figure 2-1: General Mechanism of FGFR Inhibitors

Figure 2-2: Balversa – Mechanism of Action Against Urothelial Cancer

Figure 2-3: Mechanism of Pemazyre & Truseltiq Against Cholangiocarcinoma

Figure 3-1: FGFR Mutational Frequency by Cancer Type (%)

Figure 3-2: Roles of FGFR Inhibitors in Cancer

Figure 3-3: Investigational FGFR Inhibitors

Figure 3-4: E7090 Phase II Trial – Study Initiation & Completion Year

Figure 3-5: E7090 Phase II Fortune Trial – Study Initiation & Completion Year

Figure 3-6: E7090 Phase I Trial – Study Initiation & Completion Year

Figure 3-7: Debio 1347 Phase II Trial – Study Initiation & Completion Year

Figure 3-8: Debio 1347 Phase I-II Trial – Study Initiation & Completion Year

Figure 3-9: Futibatinib Phase II Trial – Study Initiation & Completion Year

Figure 3-10: Futibatinib & Pembrolizumab Phase II Trial – Study Initiation & Completion Year

Figure 3-11: Futibatinib & Binimetinib Phase I-II Trial – Study Initiation & Completion Year

Figure 3-12: Futibatinib & Fulvestrant Phase I-II Trial – Study Initiation & Completion Year

Figure 3-13: Rogaratinib Phase II Trial for NSCLC – Study Initiation & Completion Year

Figure 3-14: Rogaratinib Phase II Trial for GIST – Study Initiation & Completion Year

Figure 3-15: Rogaratinib Phase I-II Trial – Study Initiation & Completion Year

Figure 3-16: Rogaratinib Phase I Trial – Study Initiation & Completion Year

Figure 3-17: Derazantinib Phase II Trial – Study Initiation & Completion Year

Figure 3-18: Derazantinib Phase I-II Trial – Study Initiation & Completion Year

Figure 3-19: Derazantinib/Atezolizumab Phase II Trial – Study Initiation & Completion Year

Figure 3-20: RLY4008 Phase I Trial – Study Initiation & Completion Year

Figure 3-21: CPL304110 Phase I Trial – Study Initiation & Completion Year

Figure 4-1: Global – Number of Newly Diagnosed Cancer Cases (Million), 2020, 2025 & 2030

Figure 4-2: Global – Number of Cancer Deaths (Million), 2020, 2025 & 2030

Figure 4-3: Global – FGFR Inhibitors Market Opportunity (US\$ Million), 2020-2026

Figure 4-4: Global – Cancer Drug Market Opportunity (US\$ Billion), 2020-2026

Figure 4-5: Global – FGFR Inhibitors Market by Product (%) 2026

- Figure 5-1: US – Number of Newly Diagnosed Cancer Cases (Million), 2020-2026
- Figure 5-2: US – FGFR Inhibitors Market Opportunity (US\$ Million), 2020-2026
- Figure 5-3: US – FGFR Inhibitors Market by Product (%) 2026
- Figure 5-4: Europe – Number of Newly Diagnosed Cancer Cases (Million), 2020-2026
- Figure 5-5: Europe – FGFR Inhibitors Market Opportunity (US\$ Million), 2021-2026
- Figure 5-6: Europe – FGFR Inhibitors Market by Product (%) 2026
- Figure 5-7: Japan – Number of Newly Diagnosed Cancer Cases (Million), 2020-2026
- Figure 5-8: Japan – FGFR Inhibitors Market Opportunity (US\$ Million), 2022-2026
- Figure 5-9: Japan – FGFR Inhibitors Market by Product (%) 2026
- Figure 5-10: ROW – FGFR Inhibitors Market Opportunity (US\$ Million), 2022-2026
- Figure 5-11: ROW – FGFR Inhibitors Market by Product (%), 2026
- Figure 6-1: Global – Number of Cholangiocarcinoma Cases, 2021-2026
- Figure 6-2: Global – Cholangiocarcinoma Targeting FGFR Inhibitors Market Opportunity (US\$ Million), 2021-2026
- Figure 6-3: Global – Number of Urothelial Carcinoma Cases, 2021-2026
- Figure 6-4: Global – Urothelial Carcinoma Targeting FGFR Inhibitors Market Opportunity (US\$ Million), 2021-2026
- Figure 6-5: Global – Number of NHL Cases, 2021-2026
- Figure 6-6: Global – NHL Targeting FGFR inhibitors Market Opportunity (US\$ Million), 2023 - 2026
- Figure 6-7: Global – Number of Newly Diagnosed Lung Cancer Cases (Million), 2020-2026
- Figure 6-8: Global – Lung Cancer Targeting FGFR inhibitors Market Opportunity (US\$ Million), 2022 - 2026
- Figure 7-1: Balversa – Patent Issue & Expiration Year
- Figure 8-1: Balversa – Price for 56 Tablets Supply & Price per Unit of 3mg Tablet (US\$), July'2021
- Figure 8-2: Balversa – Price for 84 Tablets Supply & Price per Unit of 3mg Tablet (US\$), July'2021
- Figure 8-3: Balversa – Price for 28 Tablets Supply & Price per Unit of 4mg Tablet (US\$), July'2021
- Figure 8-4: Balversa – Price for 56 Tablets Supply & Price per Unit of 4mg Tablet (US\$), July'2021
- Figure 8-5: Balversa – Price for 28 Tablets Supply & Price per Unit of 5mg Tablet (US\$), July'2021
- Figure 8-6: Balversa – Initial & Maintenance Dose (mg/Day)
- Figure 8-7: Balversa – Initial Dose After Reduction (mg/Day)
- Figure 8-8: Balversa – Maintenance Dose After Reduction (mg/Day)
- Figure 9-1: Pemazyre – Approval Year by Region

- Figure 9-2: Pemazyre – Patent Issue & Expiration Year
- Figure 10-1: US – Price for 14 Tablets Supply & Price per Unit of Various Doses of Pemazyre (US\$), July'2021
- Figure 10-2: Europe – Price for 14 Tablets Supply & Price per Unit of Various Doses of Pemazyre (US\$), July'2021
- Figure 10-3: Pemazyre – Duration of Single Treatment Cycle by Phase (days)
- Figure 10-4: Pemazyre – Initial & Reduced Dose (mg/day)
- Figure 10-5: Global - Pemazyre Quarterly Sales (US\$ Million), 2020
- Figure 11-1: Truseltiq – FDA Approval & Orphan Designation Year
- Figure 11-2: Truseltiq – Patent Issue & Expiration Year
- Figure 12-1: Truseltiq – Price for 42 Capsules Supply & Price per Unit of Dose 125mg (US\$), August'2021
- Figure 12-2: Truseltiq – Price for 42 Capsules Supply & Price per Unit of Dose 50mg (US\$), August'2021
- Figure 12-3: Truseltiq – Price for 63 Capsules Supply & Price per Unit of Dose 75mg (US\$), August'2021
- Figure 12-4: Truseltiq – Price for 21 Capsules Supply & Price per Unit of Dose 100mg (US\$), August'2021
- Figure 12-5: Truseltiq – Duration of Single Treatment Cycle by Phase (days)
- Figure 12-6: Truseltiq – Initial & Reduced Dose (mg/day)
- Figure 13-1: Global – Balversa Sales Forecast (US\$ Million), 2021-2026
- Figure 13-2: US – Balversa Sales Forecast (US\$ Million), 2021-2026
- Figure 13-3: Europe – Balversa Sales Forecast (US\$ Million), 2022-2026
- Figure 13-4: Japan – Balversa Sales Forecast (US\$ Million), 2022-2026
- Figure 13-5: ROW – Balversa Sales Forecast (US\$ Million), 2022-2026
- Figure 13-6: Global – Pemazyre Sales Forecast (US\$ Million), 2021-2026
- Figure 13-7: US – Pemazyre Sales Forecast (US\$ Million), 2021-2026
- Figure 13-8: Europe – Pemazyre Sales Forecast (US\$ Million), 2022-2026
- Figure 13-9: Japan – Pemazyre Sales Forecast (US\$ Million), 2022-2026
- Figure 13-10: ROW – Pemazyre Sales Forecast (US\$ Million), 2022-2026
- Figure 13-11: Global – Truseltiq Sales Forecast (US\$ Million), 2021-2026
- Figure 13-12: US – Truseltiq Sales Forecast (US\$ Million), 2021-2026
- Figure 13-13: Europe – Truseltiq Sales Forecast (US\$ Million), 2022-2026
- Figure 13-14: Japan – Truseltiq Sales Forecast (US\$ Million), 2022-2026
- Figure 13-15: ROW – Truseltiq Sales Forecast (US\$ Million), 2022-2026
- Figure 14-1: Pemazyre – Number of Clinical Trials by Phase, July'2021
- Figure 14-2: Pemazyre – Number of Clinical Trials by Phase, July'2021
- Figure 14-3: Pemazyre – Number of Clinical Trials by Development Status, July'2021
- Figure 14-4: Pemazyre – Number of Clinical Trials by Development Status (%),

July'2021

Figure 14-5: Pemazyre – Number of Clinical Trials by Region, July'2021

Figure 15-1: Global – Number of FGFR Inhibitors Drugs in Clinical Trials by Phase, 2021 till 2026

Figure 15-2: Global – Number of FGFR Inhibitors Drugs in Clinical Trials by Company, 2021 till 2026

Figure 15-3: Global – Number of FGFR Inhibitors Drugs in Clinical Trials by Patient Segment, 2021 till 2026

Figure 15-4: Global – Number of FGFR Inhibitors Drugs in Clinical Trials by Country, 2021 till 2026

Figure 17-1: Global FGFR Market Drivers

Figure 17-2: Challenges for Global FGFR Inhibitors Market

Figure 17-3: US – Annual Treatment Cost Comparison Using Various Drugs (US\$), August'2021

List Of Tables

LIST OF TABLES

Table 6-1: Global - Estimated Adoption Rates for Cholangiocarcinoma Targeting FGFR Inhibitors, 2021-2026

Table 6-2: Global - Estimated Adoption Rates for Cholangiocarcinoma Targeting FGFR Inhibitors, 2021-2026

Table 6-3: Global - Estimated Adoption Rates for NHL Targeting FGFR Inhibitors, 2021-2026

Table 6-4: Global - Estimated Adoption Rates for Lung Cancer Targeting FGFR Inhibitors, 2021-2026

I would like to order

Product name: Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity & Clinical Trials Insight 2026

Product link: <https://marketpublishers.com/r/G8F829EECFDDEN.html>

Price: US\$ 2,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G8F829EECFDDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

